High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis.
about
HMGB1 in health and disease.The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eyeTreatment of allergic children - Where is the progress (for the practicing allergist)?An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.Investigational drugs in dry eye disease.Corneal backward scattering and higher-order aberrations in children with vernal keratoconjunctivitis and normal topography.Vitamin D levels in children affected by vernal keratoconjunctivitis.Vernal keratoconjunctivitis treated with omalizumab: A case series.The Study of Interleukin-17 Level in Vernal Keratoconjunctivitis Disease and its Relationship between Symptom and Sign Severity.High-Mobility Group Box 1 in Dry Eye Inflammation.Vascular Endothelial Growth Factor (VEGF) Serological and Lacrimal Signaling in Patients Affected by Vernal Keratoconjunctivitis (VKC)Tear Ferning Test and Pathological Effects on Ocular Surface before and after Topical Cyclosporine in Vernal Keratoconjunctivitis PatientsVernal Keratoconjunctivitis and immune-mediated diseases: One unique way to symptom control?
P2860
Q34622835-43B6922B-9736-41CA-9016-0F8B41BAA1F6Q36039088-F2759571-029A-46AE-9280-F763A8568399Q38809512-FF9A1E9F-B4D8-4576-A0C5-8CB4DEA6A419Q38909557-ABF403A9-2437-49E2-A859-FA14BCC93E8BQ38984001-2182AFBC-0B7C-42DA-AB78-2839C84BC16AQ47624669-C5A7744F-D24F-4AC3-BFC3-28A25352FD64Q47650856-E1AFF9F3-0901-4D7D-9862-BC70C823DEC6Q48096579-E57CBEB6-627A-4277-8D8B-BF6442627C36Q51639647-DB37C40E-DCB4-4755-BD3D-8191D3FF730EQ55010929-4D877408-C82A-48D6-A80B-224C2FD744D3Q57300310-02687C51-96FC-4391-BD52-F3FDBE6740E1Q58567799-E9C85DA2-772D-4B27-9B3A-E47B8BFBC230Q59259795-0F7AE076-2904-427B-AEF5-4E7EEDC61248
P2860
High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
High-mobility group box-1 (HMG ...... y vernal keratoconjunctivitis.
@en
High-mobility group box-1
@nl
type
label
High-mobility group box-1 (HMG ...... y vernal keratoconjunctivitis.
@en
High-mobility group box-1
@nl
prefLabel
High-mobility group box-1 (HMG ...... y vernal keratoconjunctivitis.
@en
High-mobility group box-1
@nl
P2093
P2860
P356
P1476
High-mobility group box-1 (HMG ...... y vernal keratoconjunctivitis.
@en
P2093
Alessandra Zicari
Azzurra Cesoni Marcelli
Camilla Celani
Emanuela Mari
Francesca Occasi
Marzia Duse
Valeria Lollobrigida
P2860
P356
10.1111/PAI.12142
P577
2013-11-17T00:00:00Z